

Special Issue

Treatment of Mastitis in Dairy Cattle, 2nd Edition

Message from the Guest Editors

Mastitis is the disease for which approximately 75% of antibiotic doses are used in dairy cows. Mastitis treatment is now changing significantly in many countries. The goal of avoiding antibiotic resistance and the optimization of therapy, considering antibiotic minimization, efficacy optimization, and user interests, lead to differentiated and practical therapy concepts. Research papers addressing diagnostic, therapeutic, epidemiological, psychological, and legal aspects are welcome. **Keywords:** targeted mastitis treatment; antimicrobial resistance; therapy-decisive diagnostics; cure rates; compliance; user questions

Guest Editors

Dr. Volker Krömker

Department of Microbiology, Faculty of Mechanical and Bioprocess Engineering, University of Applied Sciences and Arts, 30453 Hannover, Germany

Dr. Paolo Moroni

Department of Veterinary Medicine and Animal Science, University of Milan, Via dell'Università 1, 26900 Lodi, Italy

Deadline for manuscript submissions

closed (31 December 2023)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/157075

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)